Inflammation mediated metastasis: Immune induced epithelial-to-mesenchymal transition in inflammatory breast cancer cells

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Cohen, Evan N ^a,b   Gao, Hui ^a   Anfossi, Simone ^a,b   Mego, Michal ^c   Reddy, Neelima G ^a   Debeb, Bisrat ^a   Giordano, Antonio ^a   Tin, Sanda ^a,b   Wu, Qiong ^a   Garza, Raul J ^a   Cristofanilli, Massimo ^d   Mani, Sendurai A ^a,b   Croix, Denise A ^e   Ueno, Naoto T ^a,b   Woodward, Wendy A ^a,b   Luthra, Raja ^a   Krishnamurthy, Savitri ^a   Reuben, James M ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Roche Diagnostics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VIMENTIN; CYTOKINE;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EPITHELIAL MESENCHYMAL TRANSITION; FN1 GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INFLAMMATORY BREAST CANCER; MARKER GENE; METASTASIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TGM2 GENE; VIM GENE; ZEB1 GENE; BLOOD; FEMALE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PILOT STUDY; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR EMBOLISM; TUMOR MICROENVIRONMENT;

CELL LINE, TUMOR; CYTOKINES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84941624968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132710     Document Type: Article

References (56)

1. Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B, et al. Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition? Int J Cancer. 1995; 62 (4):382-5. Epub 1995/08/09. PMID: 7635562.
2. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, et al. Inflammatory breast cancer: what we know and what we need to learn. The oncologist. 2012; 17(7):891-9. doi:10.1634/theoncologist.2012-0039 PMID: 22584436; PubMed Central PMCID: PMC3399643.
3. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22 (3):515-23. Epub 2010/07/07. doi:10.1093/annonc/mdq345 PMID: 20603440; PubMed Central PMCID: PMC3105293.
4. Mourali N, Levine PH, Tabanne F, Belhassen S, Bahi J, Bennaceur M, et al. Rapidly progressing breast cancer (poussee evolutive) in Tunisia: studies on delayed hypersensitivity. Int J Cancer. 1978; 22(1):1- 3. Epub 1978/07/15. PMID: 681022.
5. Mohamed MM, Cavallo-Medved D, Sloane BF. Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer. Biol Chem. 2008; 389(8):1117-21. Epub 2008/08/20. doi:10.1515/BC.2008.117 PMID: 18710343; PubMed Central PMCID: PMC3402350.
6. Mohamed MM. Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: A mechanism mediated by IL-8 signaling pathway. Cell Commun Signal. 2012; 10(1):3. Epub 2012/02/11. doi:10.1186/1478-811X-10-3 PMID: 22321604; PubMed Central PMCID: PMC3293033.
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119 (6):1420-8. Epub 2009/06/03. doi:10.1172/JCI39104PMID: 19487818; PubMed Central PMCID: PMC2689101.
8. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000; 2(2):76-83. Epub 2000/02/03. doi:10.1038/35000025 PMID: 10655586.
9. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002; 62(6):1613-8. Epub 2002/03/26. PMID: 11912130.
10. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005; 24 (14):2375-85. Epub 2005/01/28. doi:10.1038/sj.onc.1208429 PMID: 15674322.
11. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn. 2005; 233(3):706-20. Epub 2005/06/07. doi:10.1002/dvdy.20345 PMID: 15937929.
12. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117(7):927-39. Epub 2004/06/24. doi:10.1016/j.cell.2004.06.006 PMID: 15210113.
13. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007; 104(24):10069-74. Epub 2007/06/01. doi:10.1073/pnas.0703900104 PMID: 17537911; PubMed Central PMCID: PMC1891217.
14. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, et al. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One. 2010; 5(10):e13390. Epub 2010/10/23. doi:10.1371/journal.pone.0013390 PMID: 20967228; PubMed Central PMCID: PMC2953521.
15. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One. 2011; 6(6): e20701. Epub 2011/06/21. doi:10.1371/journal.pone.0020701 PMID: 21687668; PubMed Central PMCID: PMC3110765.
16. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer. 2012; 130(4):808-16. Epub 2011/03/10. doi:10.1002/ijc.26037 PMID: 21387303; PubMed Central PMCID: PMC3169728.
17. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Molecular cancer therapeutics. 2012; 11(11):2526-34. doi:10.1158/1535-7163.MCT-12-0460 PMID: 22973057; PubMed Central PMCID: PMC3500676.
18. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol. 2004; 202(3):265-73. Epub 2004/03/03. doi:10.1002/path.1515 PMID: 14991891.
19. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001; 61 (13):5231-41. Epub 2001/06/30. PMID: 11431364.
20. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin's dark side: Possible role in tumor progression. Biochim Biophys Acta. 2012; 1826(1):23-31. Epub 2012/03/24. doi:10.1016/j.bbcan.2012.03.002 PMID: 22440943; PubMed Central PMCID: PMC3362679.
21. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFbeta/TNF(alpha)-mediated epithelial- mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011; 71(13):4707-19. Epub 2011/05/11. doi:10.1158/0008-5472.CAN-10-4554 PMID: 21555371; PubMed Central PMCID: PMC3129359.
22. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial- mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009; 28 (33):2940-7. Epub 2009/07/08. doi:10.1038/onc.2009.180 PMID: 19581928.
23. Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res. 2000; 6(5):1671-7. Epub 2000/05/18. PMID: 10815885.
24. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 2005; 19(11):1905-11. Epub 2005/09/10. doi:10.1038/sj.leu.2403933 PMID: 16151467.
25. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014; 9(1):e83113. doi:10.1371/journal.pone.0083113PMID: 24416156; PubMed Central PMCID: PMC3885405.
26. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, et al. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One. 2010; 5 (8):e12180. Epub 2010/09/03. doi:10.1371/journal.pone.0012180 PMID: 20808935; PubMed Central PMCID: PMC2922340.
27. Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin- 6. British journal of cancer. 1999; 79(5-6):707-17. doi:10.1038/sj.bjc.6690114 PMID: 10070858; PubMed Central PMCID: PMC2362677.
28. Reuben JM, Lee BN, Paul M, Kline MW, Cron SG, Abramson S, et al. Magnitude of IFN-gamma production in HIV-1-infected children is associated with virus suppression. J Allergy Clin Immunol. 2002; 110 (2):255-61. Epub 2002/08/10. PMID: 12170266.
29. Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, et al. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012; 7(10):e46536. doi:10.1371/journal.pone.0046536 PMID: 23094027; PubMed Central PMCID: PMC3477108.
30. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010; 4:35-41. Epub 2010/08/11. PMID: 20697531; PubMed Central PMCID: PMC2914277.
31. Spurgeon SL, Jones RC, Ramakrishnan R. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One. 2008; 3(2):e1662. doi:10.1371/journal.pone.0001662 PMID: 18301740; PubMed Central PMCID: PMC2244704.
32. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006; 106(11):2437-44. Epub 2006/04/15. doi:10.1002/cncr.21854 PMID: 16615096.
33. Levine PH, Hashmi S, Minaei AA, Veneroso C. Inflammatory breast cancer clusters: A hypothesis. World journal of clinical oncology. 2014; 5(3):539-45. doi:10.5306/wjco.v5.i3.539 PMID: 25114867; PubMed Central PMCID: PMC4127623.
34. Pogo BG, Holland JF, Levine PH. Human mammary tumor virus in inflammatory breast cancer. Cancer. 2010; 116(11 Suppl):2741-4. doi:10.1002/cncr.25179 PMID: 20503403.
35. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast cancer research: BCR. 2008; 10(2):R25. doi:10.1186/bcr1982 PMID: 18366788; PubMed Central PMCID: PMC2397524.
36. Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Modern pathology: An official journal of the United States and Canadian Academy of Pathology, Inc. 2001; 14(5):458-64. doi:10.1038/modpathol.3880334 PMID: 11353057.
37. Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999; 59(20):5079-84. PMID: 10537277.
38. Singh R, Shankar BS, Sainis KB. TGF-beta1-ROS-ATM-CREB signaling axis in macrophage mediated migration of human breast cancer MCF7 cells. Cellular signalling. 2014. doi:10.1016/j.cellsig.2014.03.028 PMID: 24705025.
39. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC cancer. 2011; 11:130. doi:10.1186/1471-2407-11-130 PMID: 21486440; PubMed Central PMCID: PMC3095565.
40. Medler TR, Coussens LM. Duality of the immune response in cancer: lessons learned from skin. The Journal of investigative dermatology. 2014; 134(e1):E23-8. doi:10.1038/skinbio.2014.5 PMID: 25302470.
41. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Molecular immunology. 2002; 39 (9):531-6. PMID: 12431386.
42. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science. 2013; 339(6117):286-91. doi:10.1126/science.1232227 PMID: 23329041; PubMed Central PMCID: PMC3591506.
43. Jung U, Foley JE, Erdmann AA, Eckhaus MA, Fowler DH. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood. 2003; 102 (9):3439-46. doi:10.1182/blood-2002-12-3936 PMID: 12855580.
44. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, et al. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasisfree survival. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2014; 25(2):358-65. doi:10.1093/annonc/mdt496 PMID: 24299959; PubMed Central PMCID: PMC3905779.
45. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011; 19(3):372-86. doi:10.1016/j.ccr.2011.01.036 PMID: 21397860; PubMed Central PMCID: PMC3072410.
46. Eckert MA, Yang J. Targeting invadopodia to block breast cancer metastasis. Oncotarget. 2011; 2 (7):562-8. PMID: 21725138; PubMed Central PMCID: PMC3248174.
47. van Golen KL, Cristofanilli M. The Third International Inflammatory Breast Cancer Conference. Breast cancer research: BCR. 2013; 15(6):318doi:10.1186/bcr3571PMID: 24188125; PubMed Central PMCID: PMC3978691.
48. Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res. 2011; 9(12):1644-57. Epub 2011/10/19. doi:10.1158/1541-7786.MCR-11-0371 PMID: 22006115.
49. Starsichova A, Kubala L, Lincova E, Pernicova Z, Kozubik A, Soucek K. Dynamic Monitoring of Cellular Remodeling Induced by the Transforming Growth Factor-beta1. Biol Proced Online. 2009; 11:316-24. Epub 2009/09/17. doi:10.1007/s12575-009-9017-9 PMID: 19756912; PubMed Central PMCID: PMC3056018.
50. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. Epub 2008/05/20. doi:10.1016/j.cell.2008.03.027 PMID: 18485877; PubMed Central PMCID: PMC2728032.
51. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Molecular cell. 2012; 47(4):570-84. doi:10.1016/j.molcel.2012.06.014 PMID: 22819326; PubMed Central PMCID: PMC3432419.
52. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: A meta-analysis. Journal of the National Cancer Institute. 2008; 100(20):1439-47. doi:10.1093/jnci/djn324 PMID: 18840819.
53. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002; 106(16):2041-2. PMID: 12379569.
54. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, et al. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem cells translational medicine. 2014; 3(7):849-56. doi:10.5966/sctm.2013-0204 PMID: 24833589; PubMed Central PMCID: PMC4073823.
55. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, et al. Statin use in primary inflammatory breast cancer: A cohort study. British journal of cancer. 2013; 109(2):318-24. doi:10.1038/bjc.2013.342 PMID: 23820253; PubMed Central PMCID: PMC3721387.
56. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 2013; 73(8):2418-27. doi:10.1158/0008-5472.CAN-12-2432 PMID: 23436798.